HAP Trading’s AbCellera Biologics ABCL Stock Holding History

HAP Trading’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11,474	Closed	-$203K	–	2390
2021 Q2	$252K	Buy	+11,474	New	+$316K	0.01%	917

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HAP Trading's ABCL Position: Q3 2021 in Review

HAP Trading sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 11,474 shares — an estimated $203K sold.

HAP Trading first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $252K in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

HAP Trading reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
HAP Trading sold 11,474 AbCellera Biologics shares in Q3 2021, an estimated $203K.
HAP Trading first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
HAP Trading's AbCellera Biologics position peaked at $252K in Q2 2021.
116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on HAP Trading's 13F filing for Q3 2021, filed 10 Nov 2021.